Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
    • Sjögren’s Disease
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: pain

FDA Approves Denosumab for Glucocorticoid-Induced Osteoporosis

Michele B. Kaufman, PharmD, BCGP  |  June 11, 2018

Denosumab is now approved to treat adults with glucocorticoid-induced osteoporosis…

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:denosumabFDAGlucocorticoid-Induced OsteoporosisOsteoporosisosteoporosis treatmentsU.S. Food and Drug Administration (FDA)

Researchers Compare Nonsurgical Knee OA Treatments

Michele B. Kaufman, PharmD, BCGP  |  May 23, 2018

According to new research, knee OA patients reported greater pain relief from intra-articular corticosteroids, but naproxen was more effective at improving function…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:intra-articular corticosteroidskneeKnee Osteoarthritis (OA)naproxenPainPain Management

Healthcare Providers Should Encourage Exercise for OA Patients

Lara C. Pullen, PhD  |  May 23, 2018

A systemic review supports the ideas that exercise benefits the physical and mental health of patients experiencing pain related to hip and/or knee osteoarthritis (OA). Overall, research indicates that patients who exercised had slightly lower rates of pain and greater physical function, as well as slightly improved self-efficacy and social function…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:ExerciseExercise/physical therapyhiphip painkneeKnee Osteoarthritis (OA)knee painosteoarthritis (OA)

ACR/ARHP Members Call on Congress to Restore Patients’ Voices

From the College  |  May 21, 2018

WASHINGTON, D.C.—The ACR hosted the 2018 Advocacy Leadership Conference in Washington, D.C., on May 16–17. Rheumatology professionals from around the country flew to our nation’s capitol to attend the conference, where advocates heard from key policymakers and spoke with lawmakers about the issues that affect the rheumatology community—and what ACR/ARHP members can do to influence policy….

Filed under:From the CollegeLegislation & Advocacy Tagged with:2018 ACR/ARHP Leadership ConferenceAssociation of Rheumatology Professionals (ARP)Capitol Hill fly-inMichael Burgesspharmacy benefit managers (PBMs)restore patients’ voicesRestoring the Patient’s Voice Act

HCV-Associated Cryoglobulinemic Vasculitis Resolves after Virologic Cure

Will Boggs MD  |  May 18, 2018

NEW YORK (Reuters Health)—Cryoglobulinemic vasculitis associated with hepatitis C virus (HCV) infection resolves after effective treatment with direct-acting antivirals (DAAs), with most patients remaining in remission for two or more years, researchers from Spain report. “Most clinical manifestations of the disease improve over time, but some patients may have a clinical recurrence of their disease…

Filed under:ConditionsVasculitis Tagged with:cryoglobulinemic vasculitisdirect-acting antivirals (DAAs)hepatitis C virus (HCV)virologic cure

Ethics Forum: Righting the Wrong Diagnosis

Joseph L. Green, DO  |  May 18, 2018

A 54-year-old woman is establishing care in your clinic after retirement of her previous rheumatologist. Your review of her records suggests that she was diagnosed with systemic lupus erythematosus seven years ago on the basis of symptoms of body pain and fatigue, and serologic evidence of positive ANA 1:40 (speckled) and borderline anti-SSB antibody. She…

Filed under:Ethics Tagged with:DiagnosisEthics

How Footwear Affects Patients with Medial Knee Osteoarthritis

Carina Stanton  |  May 18, 2018

A patient’s gait, or how they walk, is an important predictor of the biomechanical load distribution that affects osteoarthritis (OA). This understanding comes from a growing body of literature in bio­mechanics to test and treat patients with OA, which takes into account a very practical treatment: a patient’s shoes. A focus on flexible footwear, along…

Filed under:Osteoarthritis and Bone Disorders Tagged with:footwearGait Analysisknee osteoarthritis

FDA to Review Abuse-Deterrent Oxycodone Capsule

Michele B. Kaufman, PharmD, BCGP  |  May 18, 2018

FDA to Review Abuse-Deterrent Oxycodone Capsule In June, the FDA will discuss the New Drug Application for Remoxy ER at an Advisory Committee meeting. Remoxy ER is a 12-hour, abuse-deterrent, extended-release oxycodone in a capsule formulation.1 The capsule contains a sticky, thick, high-viscosity formulation to deter unapproved drug administration routes, including injection, smoking or snorting….

Filed under:Drug Updates Tagged with:adalimumabNSAIDsOxycodoneplaque psoriasistildrakizumab-asmn

Tips & Tools for Dealing with Bad Patient Outcomes

Larry Beresford  |  May 18, 2018

Bad things happen to good rheumatologists—and to their patients—and can have profound personal and professional consequences for the doctor. Sometimes recommended treatments can have predictable, but devastating, side effects. Even if the rheumatologist does everything right according to evidence-based best practice, patients can still have bad outcomes, even die—with resulting feelings of sadness, anger, guilt…

Filed under:Professional Topics Tagged with:burnout

Rheumatology Can Use MACRA to Drive Healthcare Improvements

Terence W. Starz, MD, Theodore Pincus, MD, & Janet Bahr, NP, on behalf of the ARHP Practice Committee  |  May 18, 2018

We have entered the second year of the Medicare Access and CHIP (Children’s Health Insurance Program) Reauthorization Act (MACRA) of 2015. It’s no secret that the costs of medical care—17.1% of the U.S. gross national product compared with 9.8% in Great Britain, 10.7% in Canada and 11.6% in France—have become an overwhelming driver for change….

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:alternative payment models (APMs)APMMACRAMedicare Access and CHIP Reauthorization ActMerit-Based Incentive PaymentMIPS

  • « Previous Page
  • 1
  • …
  • 112
  • 113
  • 114
  • 115
  • 116
  • …
  • 243
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences